A detailed history of Met Life Investment Management, LLC transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 6,940 shares of FHTX stock, worth $56,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,940
Holding current value
$56,005
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.05 - $8.0 $35,047 - $55,520
6,940 New
6,940 $39,000
Q3 2023

May 09, 2024

BUY
$5.0 - $9.87 $57,225 - $112,962
11,445 New
11,445 $57,000
Q2 2023

Apr 29, 2024

BUY
$5.37 - $8.84 $61,459 - $101,173
11,445 New
11,445 $80,000
Q2 2023

Aug 10, 2023

BUY
$5.37 - $8.84 $61,459 - $101,173
11,445 New
11,445 $80,000
Q4 2022

Jun 14, 2023

BUY
$5.44 - $9.46 $74,158 - $128,958
13,632 New
13,632 $86,000
Q3 2022

Jun 14, 2023

BUY
$7.52 - $18.01 $102,512 - $245,512
13,632 New
13,632 $116,000
Q2 2022

Jun 20, 2023

BUY
$8.48 - $16.84 $115,599 - $229,562
13,632 New
13,632 $185,000
Q1 2022

May 10, 2024

BUY
$8.87 - $22.1 $120,915 - $301,267
13,632 New
13,632 $207,000
Q1 2022

Jun 20, 2023

BUY
$8.87 - $22.1 $120,915 - $301,267
13,632 New
13,632 $207,000
Q1 2022

Mar 22, 2023

BUY
$8.87 - $22.1 $43,897 - $109,372
4,949 Added 57.0%
13,632 $207,000
Q1 2022

May 12, 2022

BUY
$8.87 - $22.1 $43,897 - $109,372
4,949 Added 57.0%
13,632 $208,000
Q4 2021

Jun 21, 2023

BUY
$10.79 - $22.87 $93,689 - $198,580
8,683 New
8,683 $198,000
Q3 2021

May 17, 2024

BUY
$8.33 - $15.02 $72,329 - $130,418
8,683 New
8,683 $120,000
Q3 2021

Jun 21, 2023

BUY
$8.33 - $15.02 $72,329 - $130,418
8,683 New
8,683 $120,000
Q3 2021

Mar 22, 2023

SELL
$8.33 - $15.02 $41,225 - $74,333
-4,949 Reduced 36.3%
8,683 $120,000
Q3 2021

Nov 15, 2021

BUY
$8.33 - $15.02 $72,329 - $130,418
8,683 New
8,683 $121,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $336M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.